Uncategorized

SciFluor Life Sciences Awarded Second U.S. Patent for Integrin αvβ3 (SF0166) Inhibitors Designed for the Topical Treatment of Retinal Disease

by Business Wire • 2016/03/09 • 0 Comments

CAMBRIDGE, Mass.--(BUSINESS WIRE)--SciFluor Life Sciences announced today that the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent No. 9,266,884 with claims covering the use of the novel compound SF0166.

← Medicare Proposes Change in Part B Drug Payments

One-year Outcomes Data from Clinical Trial with ReVision Optics’ Raindrop® Near Vision Inlay for Treating Presbyopia Published in Ophthalmology, the Journal of the American Academy of Ophthalmology →

Post navigation